Skip to main content
SpringerLink
Log in

Rosiglitazone

A Review of its Use in the Management of Type 2 Diabetes Mellitus

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Rosiglitazone, a thiazolidinedione with a different side chain from those of troglitazone and pioglitazone, reduces plasma glucose levels and glucose production and increases glucose clearance in patients with type 2 diabetes mellitus. Insulin sensitivity, pancreatic β-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone.

Double-blind trials of 8 to 26 weeks of rosiglitazone 4 or 8 mg/day monotherapy indicate significant decreases in fasting plasma glucose (−2 to −3 mmol/L with 8 mg/day) and glycosylated haemoglobin levels [HbA1c; −0.6 to −0.7% (−0.8 to −1.1% in drug-naive patients) with 8 mg/day]. Significant decreases in hyperglycaemic markers occurred when rosiglitazone was combined with metformin (HbA1c −0.8 to −1.0%), a sulphonylurea (−1.4%) or insulin (−1.2%) for 26 weeks versus little change with active comparator monotherapy. Efficacy was maintained in trials of ≤2 years, and was also apparent in various ethnic subgroups, elderly patients, and both obese and nonobese patients. Rosiglitazone is currently not indicated in combination with injected insulin. It should be administered in conjunction with diet and exercise regimens.

Rosiglitazone is generally well tolerated. Despite rare individual reports of liver function abnormalities in rosiglitazone recipients, the incidence of these in clinical trials (≤2 years’ duration) was similar to that in placebo and active comparator groups. Fluid retention associated with rosiglitazone may be the cause of the increased incidence of anaemia in clinical trials, and also means that patients should be monitored for signs of heart failure during therapy. Although bodyweight is increased overall with rosiglitazone therapy, increases are in subcutaneous, not visceral, fat; hepatic fat is decreased.

The pharmacokinetic profile of rosiglitazone is not substantially altered by age or renal impairment, nor are there important drug interactions. Rosiglitazone is not indicated in patients with active liver disease or increased liver enzymes.

Conclusions: Oral rosiglitazone 4 or 8 mg/day provides significant antihyperglycaemic efficacy and is generally well tolerated, both as monotherapy and in combination with other antihyperglycaemic agents, in patients with type 2 diabetes mellitus who do not have active liver disease. Long-term data are required before conclusions can be drawn about the clinical significance of positive changes to surrogate markers of cardiovascular disease risk and improvements to pancreatic β-cell function. Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus.

Pharmacodynamic Profile

Rosiglitazone is a thiazolidinedione drug used for the treatment of type 2 diabetes mellitus. The side chain of this oral antihyperglycaemic agent differs markedly from those of the related troglitazone and pioglitazone. Binding of rosiglitazone to the peroxisome proliferator-activated receptor-γ results in reduced plasma glucose levels and endogenous glucose production, and increased glucose clearance in patients with type 2 diabetes mellitus.

Rosiglitazone has several pharmacodynamic effects that could ameliorate the increased risk of cardiovascular disease in patients with type 2 diabetes mellitus. Insulin resistance is decreased, as are plasma levels of small dense atherogenic low-density lipoprotein-cholesterol (LDL-C) particles, despite an initial overall increase in total LDL-C. Levels of the atheroprotective large high-density lipoprotein particles are increased. Changes in triglyceride levels are small and often not clinically significant. Diastolic blood pressure (DBP) is significantly decreased and systolic blood pressure (SBP) is slightly decreased in rosiglitazone recipients, compared to no change in DBP and a significant increase in SBP in patients receiving glibenclamide. Myocardial blood flow is increased, levels of plasminogen-activator inhibitor-1 are decreased and endothelial function appears to be improved. Rosiglitazone also reduces the excretion of urinary albumin to a greater extent than seen with glibenclamide in patients with type 2 diabetes mellitus.

While an increase in bodyweight has been associated with rosiglitazone, the increase is seen in subcutaneous fat depots rather than in visceral fat. Hepatic fat depots are decreased. Rosiglitazone appears to have little propensity for damage to hepatic cells, unlike the now withdrawn troglitazone. The incidence of liver function abnormalities in clinical trials of up to 2 years’ duration was similar in rosiglitazone, placebo and active comparator groups.

Rosiglitazone has beneficial effects on pancreatic β-cell function in obese and nonobese patients with type 2 diabetes mellitus, suggesting possible positive effects on disease progression.

Pharmacokinetic Profile

The concentration of rosiglitazone in plasma increases with the dose. Oral bioavailability is 99%. Clearance after oral administration is rapid; the elimination half-life is 3 to 4 hours. Excretion occurs mostly via the urine. Rosiglitazone is fully metabolised, mainly by N-demethylation and hydroxylation by cytochrome P450 (CYP) [primarily CYP2C8] enzymes.

Renal impairment or age did not result in clinically significant changes to the pharmacokinetics of rosiglitazone. Rosiglitazone did not interact with several other drugs metabolised by CYP enzymes (paclitaxel, warfarin, nifedipine, ethinylestradiol, norethindrone) nor with drugs commonly used in patients with type 2 diabetes mellitus (metformin, acarbose, atorvastatin, fibrates).

Therapeutic Efficacy

The efficacy of rosiglitazone in double-blind trials in patients with type 2 diabetes mellitus has been assessed using fasting plasma glucose (FPG) and glycosylated haemoglobin (HbA1c) levels. FPG and HbA1c levels decreased significantly in patients receiving monotherapy for 8 to 26 weeks with once- or twice-daily administration of rosiglitazone 4 mg/day (by 0.9 to 2.1 mmol/L and up to 0.3%, respectively) or 8 mg/day (by 2 to 3 mmol/L and 0.6 to 0.7%, respectively); increases of 0.3 to 1.1 mmol/L and 0.3 to 1.0%, respectively, were observed in patients receiving placebo. Sixty-two to 75% of these patients had received prior oral antihyperglycaemic therapy; response tended to be greater in drug-naive patients (decreases in HbA1c of 0.9% with 4 mg/day and 0.8 to 1.1% with 8 mg/day). FPG levels began to decrease after 2 to 4 weeks of therapy, and HbA1c levels began to decrease after 8 weeks. The efficacy of rosiglitazone monotherapy was retained with continued therapy in trials of up to 1 year in duration.

Monotherapy with rosiglitazone 8 mg/day for 12 months resulted in significantly greater reductions in FPG (2.3 mmol/L) than were seen in patients receiving glibenclamide (1.7 mmol/L). The differences were significant for both the full cohort and the drug-treatment naive subgroup. Changes in HbA1c were not significantly different between treatments.

The concomitant administration of rosiglitazone (for 26 weeks) to patients with type 2 diabetes mellitus inadequately controlled by monotherapy with metformin, a sulphonylurea or insulin resulted in significant decreases in FPG and HbA1c levels. FPG fell by 3.5 mmol/L with rosiglitazone 8 mg/day plus glibenclamide 20 mg/day, by 2.7 to 3.0 mmol/L with rosiglitazone 8 mg/day plus metformin 2.5 g/day and by 2.5 mmol/L with rosiglitazone 8 mg/day plus insulin (baseline 73 U/day). HbA1c fell by 1.4% with rosiglitazone plus glibenclamide, by 0.8 to 1.0% with rosiglitazone plus metformin and by 1.2% with rosiglitazone plus insulin at these same dosages. Continued monotherapy with a sulphonylurea, metformin or insulin had little effect on these parameters. There are indications that the concomitant administration of rosiglitazone and repaglinide may also be more beneficial than monotherapy with either agent.

Rosiglitazone appears to be effective in patients from differing ethnic groups (Indo-Asian, Mexican, African American and Chinese), in elderly patients, in patients with concomitant cardiovascular or renal disease, and in obese and non-obese patients.

Tolerability

Rosiglitazone is generally well tolerated in patients with type 2 diabetes mellitus. The percentage of patients reporting one or more adverse event in clinical trials was similar in rosiglitazone, placebo and active comparator groups. The tolerability of rosiglitazone in combination with other oral antihyperglycaemic drugs appears to be similar to that of rosiglitazone monotherapy. Rosiglitazone is well tolerated in older patients and in patients with renal impairment.

Oedema and congestive heart failure occurred more often in patients receiving rosiglitazone plus insulin than in those receiving insulin alone. This fluid retention may also be responsible for the anaemia seen in some patients. Case reports of liver function abnormalities that may be associated with rosiglitazone are rare. Bodyweight gains of 2 to 3kg with 26 to 52 weeks of rosiglitazone therapy are common.

Dosage and Administration

Rosiglitazone monotherapy is indicated in North America and in other countries, but not in Europe, for the treatment of adult patients with type 2 diabetes mellitus. Combination therapy with a sulphonylurea drug or metformin is indicated when monotherapy is inadequate. Rosiglitazone is not currently indicated for concomitant use with injected insulin.

Rosiglitazone should be given orally once or twice daily at a starting dosage of 4 mg/day (monotherapy and combination therapy), increased as required to 8 mg/day, with or without food, in combination with diet and exercise regimens. The dosage of the concomitant antihyperglycaemic agent should be reduced if hypoglycaemia occurs on addition of rosiglitazone. Dosage adjustments of rosiglitazone are not required for elderly patients or those with renal impairment.

Patients with active liver disease or increased liver enzymes (ALT ≥2.5 times the upper limit of normal) should not receive rosiglitazone. Hepatic monitoring is required for all patients during therapy. Rosiglitazone is not approved for use in patients with New York Heart Association Class III and IV cardiac status and, because of the possibility of fluid retention, all patients should be monitored for signs of heart failure during therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Table V
Table VI
Fig. 2
Table VII

Similar content being viewed by others

References

  1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications [web page]. 1999

  2. Ramarao P, Lal K-C. Insulin resistance: Current therapeutic approaches. Drugs Today 1999; 35(12): 895–911

    PubMed  CAS  Google Scholar 

  3. Zinman B. PPARγ agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’ ? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab 2001; 3 Suppl. 1: S34–43

    Article  PubMed  CAS  Google Scholar 

  4. Whitcomb RW, Saltiel AR. Thiazolidinediones. Expert Opin Invest Drugs 1995; 4(12): 1299–309

    Article  CAS  Google Scholar 

  5. Day C. Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med 1999; 16(3): 179–92

    Article  PubMed  CAS  Google Scholar 

  6. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002; 18: S23–9

    Article  PubMed  CAS  Google Scholar 

  7. Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999; 57: 921–30

    Article  PubMed  CAS  Google Scholar 

  8. Berger J, Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with anti-diabetic actions in db/db mice. Endocrinology 1996; 137: 4189–95

    Article  PubMed  CAS  Google Scholar 

  9. Spiegelman BM. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47(4): 507–14

    Article  PubMed  CAS  Google Scholar 

  10. Rieusset J, Auwerx J, Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 1999; 265: 265–71

    Article  PubMed  CAS  Google Scholar 

  11. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000; 129: 823–34

    Article  PubMed  CAS  Google Scholar 

  12. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans. Diabetes 1997 Aug; 46: 1319–27

    Article  PubMed  CAS  Google Scholar 

  13. Young PW, Buckle DR, Cantello BCC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharmacol Exp Ther 1998; 284: 751–9

    PubMed  CAS  Google Scholar 

  14. Parks DJ, Tomkinson NCO, Villeneuve MS, et al. Differential activity of rosiglitazone enantiomers at PPARγ. Bioorg Med Chem Lett 1998; 8(24): 3657–8

    Article  PubMed  CAS  Google Scholar 

  15. Smith SA, Holder JC, Giles R, et al. Phase I metabolites of rosiglitazone and pioglitazone are ligands for PPARγ but not PPARα; ENDO 2001, The Endocrine Society’s 83rd Annual Meeting; Abstract no. P3-60 [web page]. Available from URL: http://endoip.abstractcentral.com [Accessed 2002 Feb 15]

  16. Tai TAC, Jennermann C, Brown KK, et al. Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation. J Biol Chem 1996; 271: 29909–14

    Article  PubMed  CAS  Google Scholar 

  17. Prins J, Adams M, Holder J, et al. Thiazolidinediones promote human pre-adipocyte differentiation and activate hPPARγ [abstract no. P53]. J Endocrinol 1996 Mar; 148

  18. Digby JE, Crowley VEF, Sewter CP, et al. Depot-related and thiazolidinedione-responsive expression of uncoupling protein 2 (UCP2) in human adipocytes. Int J Obes 2000; 24: 585–92

    Article  CAS  Google Scholar 

  19. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997 Dec; 100(12): 3149–53

    Article  PubMed  CAS  Google Scholar 

  20. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 1996; 93: 5793–6

    Article  PubMed  CAS  Google Scholar 

  21. Rieusset J, Chambrier C, Bouzakri K, et al. The expression of the p85α subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor γ in human adipocytes. Diabetologia 2001; 44: 544–54

    Article  PubMed  CAS  Google Scholar 

  22. Teruel T, Smith S. Differential regulation of UCP-1 expression by rosiglitazone and Wy 14643 in brown adipocytes [abstract no. 0066]. Diabetes 1998 May; 47: A17

    Google Scholar 

  23. Digby JE, Montague CT, Sewter CP, et al. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 1998; 47: 138–41

    Article  PubMed  CAS  Google Scholar 

  24. Aubert J, Champigny O, Saint-Marc P, et al. Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Biochem Biophys Res Commun 1997; 238: 606–11

    Article  PubMed  CAS  Google Scholar 

  25. Smith U, Gogg S, Johansson A, et al. Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J 2001; 15: 215–20

    Article  PubMed  CAS  Google Scholar 

  26. Ribon V, Johnson JH, Camp HS, et al. Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA 1998; 95: 14751–6

    Article  PubMed  CAS  Google Scholar 

  27. Baumann CA, Chokshi N, Saltiel AR, et al. Cloning and characterization of a functional peroxisome proliferator activator receptor-γ-responsive element in the promoter of the CAP gene. J Biol Chem 2000 Mar 31; 275(13): 9131–5

    Article  PubMed  CAS  Google Scholar 

  28. Maeda N, Takahashi M, Funahashi T, et al. PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001 Sep; 50: 2094–9

    Article  PubMed  CAS  Google Scholar 

  29. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86(5): 1930–5

    Article  PubMed  CAS  Google Scholar 

  30. Yang C, Chang T-J, Chang J-C, et al. Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway. Diabetes 2001 Nov; 50: 2598–602

    Article  PubMed  CAS  Google Scholar 

  31. Brunmair B, Gras F, Neschen S, et al. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression. Diabetes 2001 Oct; 50: 2309–15

    Article  PubMed  CAS  Google Scholar 

  32. Barroso I, Gurnell M, Crowley VEF, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999 Dec 23; 402: 880–3

    PubMed  CAS  Google Scholar 

  33. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 2001 Dec; 44: 2210–9

    Article  PubMed  CAS  Google Scholar 

  34. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000; 106: 1305–7

    Article  PubMed  CAS  Google Scholar 

  35. Chao L, Marcus-Samuels B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000 Nov; 106(10): 1221–8

    Article  PubMed  CAS  Google Scholar 

  36. Gerich J, Dostou J, Islam N, et al. Mechanisms by which rosiglitazone improves glycaemic control in type 2 diabetes [abstract no. 771]. Diabetologia 2001; 44 Suppl. 1: 201

    Google Scholar 

  37. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25(4): 708–11

    Article  PubMed  CAS  Google Scholar 

  38. King AB, Armstrong D. Comparison of the glucose and lipid effects of rosiglitazone and pioglitazone following conversion from troglitazone treatment. Diabetes 2001, 120–1

  39. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocrine Practice 2001 30;7: 162–9

    PubMed  CAS  Google Scholar 

  40. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378–96

    Article  PubMed  CAS  Google Scholar 

  41. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303

    PubMed  CAS  Google Scholar 

  42. Eldershaw TPD, Rattigan S, Cawthorne MA, et al. Prior treatment of obese Zucker rats with the thiazolidinedione (BRL 49653) decreases insulin resistance in perfused hindlimb [abstract no. 27]. Diabetes Care 1995 Jun; 18: A16

    Google Scholar 

  43. Oakes ND, Kennedy CJ, Jenkins AB, et al. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203–10

    Article  PubMed  CAS  Google Scholar 

  44. Young PW, Cawthorne MA, Coyle PJ, et al. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes: association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 1995; 44: 1087–92

    Article  PubMed  CAS  Google Scholar 

  45. Pickavance L, Buckingham R, Wilding J. Insulin-sensitising action of rosiglitazone is enhanced by food restriction [abstract no. 674]. Diabetologia 1999 Aug; 42: 181

    Article  Google Scholar 

  46. Moore G, Pickavance L, Clapham J, et al. Insulin sensitising effect of rosiglitazone: effects on metabolism and gene expression [abstract no. 2128-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A506

    Google Scholar 

  47. Leonard TB, Bakst A, Warsi G, et al. Rosiglitazone may reduce insulin resistance related cardiovascular disease risk in patients with type 2 diabetes [abstract no. 1838-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A441

    Google Scholar 

  48. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002 Mar; 51: 797–802

    Article  PubMed  CAS  Google Scholar 

  49. Carey DG, Cowin GJ, Galloway GJ, et al. Rosiglitazone increases insulin sensitivity and reduces factors associated with insulin resistance in type 2 diabetics [abstract no. P311]. Diabetes Res Clin Pract 2000 Sep; 50 Suppl. 1: 64–5

    Article  Google Scholar 

  50. Garber A, Cobitz AR, Deacon L, et al. Rosiglitazone: effects on the insulin-resistance metabolic syndrome [web page]. Available from URL: http://endoip.abstractcentral.com [Accessed 2002 Feb 15]

  51. Thomas JC, Taylor KB. Effects of thiazolidinediones on lipoprotein subclasses in patients who are insulin resistant [abstract no. 1902-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A455

    Article  Google Scholar 

  52. Oakes ND, Camilleri S, Furier SM, et al. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 1997; 46: 935–42

    Article  PubMed  CAS  Google Scholar 

  53. Lefebvre A-M, Peinado-Onsurbe J, Leitersdorf I, et al. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 1997; 17: 1756–64

    Article  PubMed  CAS  Google Scholar 

  54. Lohray BB, Bhushan V, Rao BP, et al. Novel euglycemic and hypolipidemic agents. J Med Chem 1998; 41: 1619–30

    Article  PubMed  CAS  Google Scholar 

  55. Bakst A, Schwartz S, Fischer JS, et al. Avandia Worldwide Awareness Registry: improved metabolic control with initiation of rosiglitazone in a diabetes clinic setting [abstract no. 1791-PO]. Diabetes 2001 Jun; 50 Suppl. 2: 430

    Google Scholar 

  56. Ovalle F, Bell DSH. Differing effects of thiazolidinediones on LDL subfractions [abstract no. 1896-PO]. Diabetes 2001 Jun; 50 Suppl. 2: 453–4

    Google Scholar 

  57. Brunzell J, Cohen BR, Kreider M, et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes [abstract no. 567-P]. Diabetes 2001 Jun; 50: 141

    Google Scholar 

  58. Ovalle F, Bell DSH. Differing effects of thiazolidinediones on HDL subfractions and LP(a) [abstract no. 1930-PO]. Diabetes 2001 Jun; 50 Suppl. 1: A461–2

    Google Scholar 

  59. Stewart M, Jones NP, Kreider M, et al. Combined effects of rosiglitazone and atorvastatin on the dyslipidaemia associated with type 2 diabetes [abstract no. 854]. Diabetologia 2001; 44 Suppl. 1:222

    Google Scholar 

  60. Davidson PC, Sabbah HT, Steed RD, et al. Pioglitazone versus rosiglitazone therapy in randomized follow-up in patients previously treated with troglitazone [abstract no. 437-P]. Diabetes 2001; 50 Suppl. 2: 109

    Google Scholar 

  61. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes [published errata appear in Diabetes Care 2001; 24 (5): 973]. Diabetes Care 2001; 24: 308–15

    Article  PubMed  CAS  Google Scholar 

  62. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes [published erratum appears in J Clin Endocrinol Metab 2001; 86: 1659]. J Clin Endocrinol Metab 2001; 86: 280–8

    Article  PubMed  CAS  Google Scholar 

  63. Yue T-L, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 2001; 104: 2588–94

    Article  CAS  Google Scholar 

  64. Sidell RJ, Cole MA, Draper NJ, et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 2002 Apr; 51: 1110–7

    Article  PubMed  CAS  Google Scholar 

  65. Khandoudi N, Delerive P, Berrebi-Bertrand I, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002 May; 51: 1507–14

    Article  PubMed  CAS  Google Scholar 

  66. Phillips JW, Barringhaus KG, Sanders JM, et al. Rosiglitazone prevents the development of hyperglycemia and hyper-insulinemia and significantly reduces neointimal formation following carotid wire injury in APOE (−/−) mice fed a western diet [abstract no. 564]. Circulation 2001 Oct 23; 104 Suppl. 17: II–117

    Google Scholar 

  67. Benson GM, Grimsditch DC, Vidgeon-Hart M, et al. Rosiglitazone reduces atherosclerosis in ApoE KO mice [abstract no. 323-PP]. Diabetes 2001 Jun; 50 Suppl. 2: A80

    Google Scholar 

  68. Dogterom P, Jonkman JHG, Vallance SE. Rosiglitazone: no effect on erythropoiesis or premature red cell destruction [abstract no. 0424]. Diabetes 1999; 48 Suppl. 1: A98

    Google Scholar 

  69. Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose-level lowering. J Cardiovasc Risk 1999; 6(5): 337–46

    PubMed  CAS  Google Scholar 

  70. Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448–53

    Article  PubMed  CAS  Google Scholar 

  71. Buckingham RE, Al-Barazanji KA, Toseland CDN, et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326–34

    Article  PubMed  CAS  Google Scholar 

  72. Bakris GL, Dole JF, Porter LE, et al. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus [abstract no. 388-P]. Diabetes 2000 May; 49 Suppl. 1: 96

    Google Scholar 

  73. Law RE, Goetze S, Xi X-P, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311–8

    Article  PubMed  CAS  Google Scholar 

  74. Sutton MSJ, Dole JF, Rappaport EB. Rosiglitazone does not adversely affect cardiac structure or function in patients with type 2 diabetes [abstract no. 0438]. Diabetes 1999 May; 48 Suppl. 1: 102

    Google Scholar 

  75. Miller E, Patel J, Reichek N, et al. BRL 49653 (a thiazolidinedione) is well tolerated and has no effect on LV mass following 12 weeks treatment in NIDDM patients [abstract no. 0377]. Diabetes 1997 May; 46 Suppl. 1: 96A

    Google Scholar 

  76. Salzman A, Murphy KJ. Rosiglitazone: cardiac safety with long-term treatment in patients with type 2 diabetes [abstract no. P309]. Diabetes Res Clin Pract 2000 Sep; 50 Suppl. 1: S64

    Article  Google Scholar 

  77. Reaven P, Chen Q, Gerkin R, et al. Effect of diabetes and rosiglitazone on myocardial blood flow [abstract no. 219]. Diabetologia2001; 44 Suppl. 1: A57

    Google Scholar 

  78. McTernan PG, Eggo MC, Smith SA, et al. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human subcutaneous adipocytes [abstract no. 1132-P]. Diabetes 2001 Jun; 50 Suppl. 2: A275

    Google Scholar 

  79. Goldstein BJ, Fuell D, Menci L, et al. Rosiglitazone in combination with glibenclamide: effect on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes [abstract no. P310]. Diabetes Res Clin Pract 2000 Sep; 50 Suppl. 1: 64

    Article  Google Scholar 

  80. Dandona P, Mohanty P, Aljada A, et al. Evidence of a potent anti-inflammatory effect of rosiglitazone in mononuclear cells [abstract no. 136]. Diabetologia 2001; 44 Suppl. 1: A36

    Google Scholar 

  81. Haffner SM, Greenberg A, Weston W, et al. Effects of rosiglitazone treatment on levels of C-reactive protein and MMP9 in patients with type 2 diabetes [abstract no. 565]. Circulation 2001 Oct 23; 104 Suppl. 2: 117–8

    Google Scholar 

  82. Fuell DL, Freed MI, Greenberg AS, et al. The effect of treatment with rosiglitazone on C-reactive protein and interleukin-6 in patients with type 2 diabetes [abstract no. 1813-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A435

    Google Scholar 

  83. Smith SA, Moore G, Charlton S, et al. Rosiglitazone influences macrophage function but not monocyte/macrophage differentiation [abstract no. 1156]. Diabetes 1999 May; 48 Suppl.1: 264

    Google Scholar 

  84. Walker A, Chattington P, Buckingham R, et al. BRL 49653, a new insulin-sensitizing agent, protects against impairment of endothelial function in Zucker fatty rats [abstract no. 816]. Diabetes 1996 May; 45 Suppl. 2: 222A

    Google Scholar 

  85. Stühlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002 Mar 20; 287(11): 1420–6

    Article  PubMed  Google Scholar 

  86. Jackson SM, Parhami F, Xi X-P, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19(9): 2094–104

    Article  PubMed  CAS  Google Scholar 

  87. Fuell D, Freed MI, Greenberg A, et al. Correlation of levels of non-traditional cardiovascular risk factors with demographic and disease variables in patients with type 2 diabetes mellitus [web page]. Available from URL: http://endoip.abstractcentral.com [Accessed 2002 Feb 15]

  88. Walker AB, Naderali EK, Chattington PD, et al. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998; 47: 810–4

    Article  PubMed  CAS  Google Scholar 

  89. Knock GA, Mishra SK, Aaronson PI. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol 1999; 368: 103–9

    Article  PubMed  CAS  Google Scholar 

  90. Chinetti G, Lestavel S, Bocher V, et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001 Jan; 7(1): 53–8

    Article  PubMed  CAS  Google Scholar 

  91. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25: S33–49

    Article  Google Scholar 

  92. Bakris G, Weston WM, Rappaport EB, et al. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes [abstract no. 865]. Diabetologia 1999 Aug; 42 Suppl. 1: A230

    Google Scholar 

  93. Weston WM, Freed MI, Heise M. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes [abstract no. P197]. Diabet Med 2000 Mar; 17 Suppl. 1: 87

    Google Scholar 

  94. Wang Q, Dryden S, Frankish HM, et al. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol 1997; 122: 1405–10

    Article  PubMed  CAS  Google Scholar 

  95. Pickavance L, Tadayyon M, Widdowson P. Therapeutic index for rosiglitazone in dietary obese rats and effects on body weight and plasma leptin [abstract no. P53]. Diabet Med 1998; 15 Suppl. 2: S28

    Google Scholar 

  96. Pickavance LC, Tadayyon M, Widdowson PS, et al. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 1999; 128: 1570–6

    Article  PubMed  CAS  Google Scholar 

  97. Pearson SL, Cawthorne MA, Clapham JC, et al. The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-γ and aPd2 in adipose tissue of high-fat-fed rats. Biochem Biophys Res Commun 1996; 229: 752–7

    Article  PubMed  CAS  Google Scholar 

  98. De Vos P, Lefebvre A-M, Miller SG, et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptorγ. J Clin Invest 1996; 98: 1004–9

    Article  PubMed  Google Scholar 

  99. Horikoshi H, Hashimoto T, Fujiwara T. Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control. Prog Drug Res 2000; 54: 191–212

    Article  PubMed  CAS  Google Scholar 

  100. Carey DG, Galloway G, Dodrell D, et al. Rosiglitazone reduces hepatic fat and increases subcutaneous but not intra-abdominal fat depots [abstract no. 271]. Diabetologia 2000 Aug; 43 Suppl. 1: A68

    Google Scholar 

  101. Banerji M, Lebovitz H, Dugbartey M. Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus [abstract no. 356-P]. Diabetes 2001 Jun; 50 Suppl. 2: 90

    Google Scholar 

  102. Owen SM, Jones NP, Patwardhan R. Rosiglitazone treatment reduces gamma-glutamyltransferase levels, a marker for visceral and hepatic fat [abstract no. 488-P]. Diabetes 2000 May; 49 Suppl. 1: 120

    Google Scholar 

  103. SmithKline Beecham Pharmaceuticals. Rosiglitazone maleate tablets prescribing information. Philadelphia, PA, USA: SmithKline Beecham Pharmaceuticals, 2001 Feb

    Google Scholar 

  104. Haskins JR, Rowse P, Rahbari R, et al. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 2001; 75: 425–38

    Article  PubMed  CAS  Google Scholar 

  105. Elcock FJ, Lyon JJ, Hitchcock J, et al. Toxicity of troglitazone in cultured rat hepatocytes [abstract no. 0267]. Diabetes 1999 May; 48 Suppl. 1: 63

    Google Scholar 

  106. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials. Diabetes Care 2002 May; 25(5): 815–21

    Article  PubMed  CAS  Google Scholar 

  107. Salzman A, Patel J. Rosiglitazone therapy is not associated with hepatotoxicity [abstract no. 0408]. Diabetes 1999 May; 48 Suppl. 1: A95

    Google Scholar 

  108. Greene DA, Viberti GF, Berry RA, et al. A diabetes outcome progression trial (ADOPT) of long-term rosiglitazone, metformin, and glyburide monotherapy in drug-naive patients [abstract no. 1435-PO]. Diabetes 2000 May; 49: 343

    Google Scholar 

  109. Matejcic A, Billiard V. McMaster research team awarded $25 million for diabetes clinical trial [web page]. Available from URL: www.fhs.mcmaster.ca [Accessed 2002 May 21]

  110. Smith S, Boam D, Bretherton-Watt D, et al. Rosiglitazone increases pancreatic islet area, density and insulin content, but not insulin gene expression [abstract no. 0072]. Diabetes 1998 May; 47 Suppl. 1: A18

    Google Scholar 

  111. Moore GBT, Piercy V, Newman M, et al. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin content [abstract no. 556]. Diabetologia 1999 Aug; 42 (Suppl. 1): A150

    Google Scholar 

  112. Smith SA, Lister CA, Hughes MG, et al. The PPARγ agonist, BRL 49653, prevents onset of hyperglycemia and proteinuria in ZDF rats [abstract no. 0577]. Diabetes 1997 May; 46 Suppl. 1: 150A

    Google Scholar 

  113. Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 2001 May; 50: 1021–9

    Article  PubMed  CAS  Google Scholar 

  114. Patel J, Weston W, Hemyari P. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes mellitus [abstract no. P3-153]. The Endocrine Society’s 81st Annual Meeting Programs and Abstracts 1999, 470

  115. Matfin G, Beck S. Rosiglitazone alone or in combination with metformin gives long-term glycemic control [abstract no. P644]. 11th International Congress of Endocrinology abstract book 2000, 255

  116. Porter LE, Freed MI, Jones NP, et al. Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes [abstract no. 495-P]. Diabetes 2000 May; 49 (Suppl. 1): 122

    Google Scholar 

  117. Jones NP, Charbonnel B, Lonnqvist F, et al. Rosiglitazone reduces plasma insulin and its precursors while decreasing glycaemia in patients with type 2 diabetes [abstract no. A44]. Diabet Med 2000 Mar; 17 (Suppl. 1): 14

    Google Scholar 

  118. Deacon L, Donnelly S, Stewart M, et al. Rosiglitazone is effective in obese and non-obese patients with type 2 diabetes [abstract no. 1804-PO]. Diabetes 2001 Jun; 50 Suppl. 2: 433

    Google Scholar 

  119. Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28: 772–80

    PubMed  CAS  Google Scholar 

  120. Patel BR, Diringer K, Conrad J, et al. Population pharmacokinetics of rosiglitazone in phase III clinical trials [abstract no. PII-33]. Clin Pharmacol Ther 2000; 67(2): 123

    Google Scholar 

  121. Freed MI, Allen A, Jorkasky DK, et al. Systemic exposure to rosiglitazone is unaltered by food. Eur J Clin Pharmacol 1999; 55: 53–6

    Article  PubMed  CAS  Google Scholar 

  122. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48: 424–32

    Article  PubMed  CAS  Google Scholar 

  123. Chapelsky MC, Thompson K, Miller A. Effect of renal impairment on the pharmacokinetics of rosiglitazone (RSG) [abstract no. PIII-36]. Clin Pharmacol Ther 1999; 65(2): 185

    Article  Google Scholar 

  124. Thompson K, Zussman B, Miller A. Pharmacokinetics of rosiglitazone are unaltered in hemodialysis patients [abstract no. PIII-38]. Clin Pharmacol Ther 1999; 65(2): 186

    Article  Google Scholar 

  125. Miller AK, Inglis AL, Thompson K. Effect of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG) [abstract no. PIII-37]. Clin Pharmacol Ther 1999; 65(2): 186

    Article  Google Scholar 

  126. DiCicco R, Freed M, Allen A, et al. A study of the effect of age on the pharmacokinetics of BRL 49653C in healthy volunteers [abstract no. 24]. J Clin Pharmacol 1995 Sep; 35: 926

    Google Scholar 

  127. Yamazaki H, Suzuki M, Tane K, et al. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 2000; 30: 61–70

    Article  PubMed  CAS  Google Scholar 

  128. Harris RZ, Inglis AM, Miller AK, et al. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol 1999; 39: 1189–94

    PubMed  CAS  Google Scholar 

  129. Inglis AML, Miller AK, Culkin KT, et al. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. J Clin Pharmacol 2001; 41: 683–90

    Article  PubMed  CAS  Google Scholar 

  130. Di Cicco RA, Allen A, Carr A, et al. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol 2000; 40: 1280–5

    PubMed  Google Scholar 

  131. Miller AK, Inglis AM, Culkin KT, et al. The effect of acarbose on the pharmacokinetics of rosiglitazone. Eur J Clin Pharmacol 2001 May; 57: 105–9

    Article  PubMed  CAS  Google Scholar 

  132. Freed MI, Miller A, Jorkasky DK, et al. Rosiglitazone pharmacokinetics are not affected by coadministration of ranitidine [abstract no. 1365]. Diabetes 1998 May; 47 (Suppl.1): A353

    Google Scholar 

  133. Di Cicco RA, Miller AK, Patterson S, et al. Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. J Clin Pharmacol 2000; 40: 1516–21

    PubMed  Google Scholar 

  134. Cohen BR, Kreider M, Biswas N, et al. Rosiglitazone in combination with an HMG CoA reductase inhibitor: safety and effects on lipid profile in patients with type 2 diabetes [abstract no. 1884-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A451

    Google Scholar 

  135. Jones NP, Mather RA, Sautter M. Rosiglitazone treatment does not impair the triglyceride-lowering activity of fibrates in patients with type 2 diabetes mellitus [abstract no. 1507-PO]. Diabetes 2000 May; 49 (Suppl.1): A359

    Google Scholar 

  136. Culkin KT, Patterson SD, Jorkasky DK, et al. Rosiglitazone does not increase the risk of alcohol-induced hypoglycemia in diet-treated type 2 diabetics [abstract no. 1529]. Diabetes 1999 May; 48 (Suppl.1): A350

    Google Scholar 

  137. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1998 Jan; 21 Suppl. 1: S23–31

    Article  Google Scholar 

  138. Nolan JJ, Jones NP, Patwardhan R, et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabet Med 2000; 17: 287–94

    Article  PubMed  CAS  Google Scholar 

  139. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes. Diabetologia 2000; 43(3): 278–84

    Article  PubMed  CAS  Google Scholar 

  140. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999; 1: 165–72

    Article  PubMed  CAS  Google Scholar 

  141. Grunberger G, Dole JF, Freed MI. Rosiglitazone monotherapy significantly lowers HbA1c levels in treatment- naive type 2 diabetic patients [abstract no. 441-P]. Diabetes 2000 May; 49 (Suppl. 1): A109

    Google Scholar 

  142. Lönnqvist F, Charbonnel B, Jones NP, et al. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose in type 2 diabetic patients [abstract no. 869]. Diabetologia 1999 Aug; 42 (Suppl. 1): A231

    Google Scholar 

  143. Owen S, Charbonnel B, Lonnqvist F, et al. Rosiglitazone is an effective alternative to glibenclamide as first-line therapy in type 2 diabetic patients [abstract no. 868]. Diabetologia 1999 Aug; 42 Suppl. 1: A231

    Google Scholar 

  144. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999 Jun; 281(21): 2005–12

    PubMed  CAS  Google Scholar 

  145. Rosenstock J, Kreider MM, Menci L, et al. Efficacy and safety of rosiglitazone combined with glibenclamide is effective and well tolerated in type 2 diabetes patients inadequately controlled on maximum-dose glibenclamide [abstract no. P300]. Diabetes Res Clin Pract 2000 Sep; 50 Suppl. 1: S61

    Google Scholar 

  146. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695–702

    Article  PubMed  CAS  Google Scholar 

  147. Maheux P, Berry RA, Warsi G, et al. Rosiglitazone-metformin combination improves glycemic control in patients with type 2 diabetes; Poster 168; 5th Annual COA/CSEM Professional Conference; Edmonton, Alberta, Canada. 2001 Oct 17-2001

  148. Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000; 17: 40–7

    Article  PubMed  CAS  Google Scholar 

  149. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226–32

    Article  PubMed  CAS  Google Scholar 

  150. Raskin P, McGill J, Hale P, et al. Repaglinide/rosiglitazone combination therapy of type 2 diabetes. Diabetes 2001 Jun; 50 (Suppl. 2): 128–9

    Google Scholar 

  151. Jones NP, Mather RA, Owen S, et al. Rosiglitazone: long-term efficacy in combination with metformin or as monotherapy [abstract no. P307]. Diabetes Res Clin Pract 2000 Sep; 50 (Suppl. 1): 63

    Google Scholar 

  152. Jones N, Jones T, Menci L, et al. Rosiglitazone in combination with glibenclamide plus metformin is effective and well tolerated in type 2 diabetes patients [abstract no. 904]. Diabetologia 2001; 44 (Suppl. 1): 235

    Google Scholar 

  153. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus [abstract no. 421-P]. Diabetes 2001 Jun; 50 (Suppl. 2): A106

    Google Scholar 

  154. Gómez-Perez FJ, Fanghänel-Salmón G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127–34

    Article  PubMed  CAS  Google Scholar 

  155. Barnett AH, Grant PJ, Hitman GA, et al. Rosiglitazone is effective in patients of Indo- Asian ethnic origin with type 2 diabetes [abstract no. A40]. Diabet Med 2001 Apr; 18 Suppl.2: 15

    Google Scholar 

  156. Osei K, Miller EE, Everitt DE, et al. Rosiglitazone is effective and well tolerated as monotherapy in African Americans with type 2 diabetes. Diabetes 2001, 127–8

  157. Zhu X, Pan C, Li G, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulfonylureas [abstract no. 542-P]. Diabetes 2001 Jun; 50 (Suppl. 2): A135

    Google Scholar 

  158. Zhu X, Pan C, Li G, et al. Rosiglitazone in combination with sulphonylurea improves glycemic control in Chinese type 2 diabetes patients [abstract no.624a]. 11th International Congress of Endocrinology abstract book 2000, 249

  159. Beebe KL. Rosiglitazone is effective and well tolerated in patients ≥65 years with type 2 diabetes [abstract no. 854]. Diabetologia 1999 Aug; 42 (Suppl. 1): A227

    Google Scholar 

  160. Cranmer H, Jones NP, Patwardhan R. Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes [abstract no. A43]. Diabet Med 2000 Mar; 17 (Suppl. 1): 13

    Google Scholar 

  161. Jones TA, Jones NP, Sautter MC. Rosiglitazone: effective when added to metformin in obese, insulin- resistant patients with type 2 diabetes [abstract no. P308]. Diabetes Res Clin Pract 2000 Sep; 50 (Suppl. 1): 63–4

    Google Scholar 

  162. Fuell D, Zhou J, Freed MI. Effects of rosiglitazone to improve glycemic control in type 2 diabetes patients taking β-blockers; The Endocrine Society’s 83rd Annual Meeting, Denver USA [web page]. Available from URL: http://endoip.abstractcentral.com [Accessed 2002 Feb 15]

  163. Agrawal A, Jones NP, Sautter MC. Rosiglitazone added to a sulphonylurea: effective and well tolerated in patients with type 2 diabetes and mild to moderate renal impairment [abstract no. P1066]. Diabetes Res Clin Pract 2000 Sep; 50 (Suppl. 1): S257

    Article  Google Scholar 

  164. Goldstein B, Salzman A. Rosiglitazone is effective in poorly controlled type 2 diabetes patients [abstract no. P186]. Diabet Med 2000 Mar; 17 (Suppl. 1): 84

    Google Scholar 

  165. Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 2001; 35: 123–4

    Article  PubMed  CAS  Google Scholar 

  166. SB/Bristol Avandia lipid adverse effect diminishes over two months — label. FDC Pink 1999; 61: 20

    Google Scholar 

  167. Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 132: 121–4

    CAS  Google Scholar 

  168. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone [see comments]. Ann Intern Med 2000; 132: 118–21

    PubMed  CAS  Google Scholar 

  169. Ravinuthala RS, Nori U. Rosiglitazone toxicity [letter]. Ann Intern Med 2000; 133(8): 658

    PubMed  CAS  Google Scholar 

  170. Hachey DM, O’Neil MP, Force RW. Isolated elevation of alkaline phosphatase level associated with rosiglitazone [letter]. Ann Intern Med 2000; 133(9): 752

    PubMed  CAS  Google Scholar 

  171. Gouda HE, Khan A, Schwartz J, et al. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med 2001 Nov; 111: 584–5

    Article  PubMed  CAS  Google Scholar 

  172. Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure [letter; comment]. Ann Intern Med 2000; 132: 164

    PubMed  CAS  Google Scholar 

  173. Zhu X, Tan C, Li G, et al. Rosiglitazone has a favorable safety profile in Chinese type 2 diabetics with previous exposure to hepatitis B or C infection [abstract no. 1863-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A446

    Google Scholar 

  174. European Union market news. Inpharma 2000; 1249: 22

    Google Scholar 

  175. Avandia launched in UK and Germany. Scrip 2000; 2561: 21

    Google Scholar 

  176. Health Canada. Important safety information regarding Avandia® (rosiglitazone maleate) [web page]. 2001 Nov 13

  177. US Food and Drug Administration. FDA strengthens labelling for cardiovascular risks of glitazones [web page]. Available from URL: www.fda.gov [Accessed 2002 May 7]

  178. Miller JL. Rosiglitazone approved for treatment of type 2 diabetes [news]. Am J Health Syst Pharm 1999; 56: 1292–94

    PubMed  CAS  Google Scholar 

  179. King H, Auert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 Sep; 21(9): 1414–31

    Article  PubMed  CAS  Google Scholar 

  180. Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999; 20: 489–503

    Article  PubMed  CAS  Google Scholar 

  181. European DPG1. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716–30

    Google Scholar 

  182. Reynolds LR, Strange K, Anderson JW, et al. Lifestyle intervention reduces multiple risk factors in obese patients with poorly controlled insulin-requiring type 2 diabetes mellitus; ENDO 2001, The Endocrine Society’s 83rd Annual Meeting [web page]. Available from URL: http://endoip.abstractcentral.com [Accessed 2002 Feb 15]

  183. National Institute for Clinical Excellence. NICE issues guidance on rosiglitazone for type 2 diabetes [web page]. Available from URL: www.nice.org.uk [Accessed 2000 Nov 6]

  184. Mooradian AD, Chehade J, Thurmann JE. The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treat Endocrinol 2002; 1(1): 13–20

    Article  PubMed  Google Scholar 

  185. Nathan DM. Some answers, more controversy, from UKPDS. Lancet 1998 Sep 12; 352: 832–3

    Article  PubMed  CAS  Google Scholar 

  186. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352: 837–53

    Article  Google Scholar 

  187. The Diabetes Control and Complications Trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329(14): 977–86

    Article  Google Scholar 

  188. Lebovitz HE. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes. Diabetes Care 1999 Apr; 22: 41–4

    Google Scholar 

  189. European study of impact of rosiglitazone on CVD. Pract Diab Int 2001 May; 18(4): 144

    Article  Google Scholar 

  190. Stephens JM, Ramsdell JW, Braunstein S, et al. Economic comparison of six first-line drug strategies in type 2 diabetes using a Monte Carlo simulation model [abstract no. PDB8]. Value Health 2002 May-2002 30; 5: 205

    Article  Google Scholar 

  191. Oh PI, Shane LG. Cost-effectiveness and cardiovascular risk — an analysis of rosiglitazone compared with other oral hypoglycemic agents in the treatment of type 2 diabetes mellitus [abstract no. PDB4]. Value Health 2001 Mar; 4(2): 113

    Article  Google Scholar 

  192. White JJr. The cost of managing diabetes mellitus: focus on the oral pharmacologic management of type II diabetes. J Manage Care Pharm 1999; 5: 113–20

    Google Scholar 

  193. Rubin RJ, Dietrich KA, Hawk AD. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. J Clin Endocrinol Metab 1998; 83: 2635–42

    Article  PubMed  CAS  Google Scholar 

  194. Curran M. Costs and quality-of-life issues of type 2 diabetes mellitus. Scientific Meetings News (European Association for the Study of Diabetes. Brussels 28 September–2nd October, 1999 Oct 4

  195. Evans AJ, Krentz AJ. Recent developments and emerging therapies for type 2 diabetes mellitus. Drugs RD 1999; 2: 74–94

    Article  Google Scholar 

  196. Rosiglitazone for type 2 diabetes mellitus. Med Lett Drugs Ther 1999; 41: 71–3

    Google Scholar 

  197. Repaglinide and diabetes: no better than glucose-lowering sulphonamides. Prescrire Int 2001 Feb; 10(51): 9–11

    Google Scholar 

  198. Berger M, Jorgens V, Muhlhauser I. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes. Diabetes Care 1999 Apr; 22: 71–5

    Article  Google Scholar 

  199. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 Jun 15; 359(9323): 2072–7

    Article  PubMed  CAS  Google Scholar 

  200. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61(11): 1625–60

    Article  PubMed  CAS  Google Scholar 

  201. Mounting dissatisfaction with NICE in the UK. Pharmaco Economics Outcomes News 2001, 3 Mar

  202. Insulin manufacturer expresses concerns over NICE guidance. Pharm J 2001; 266: 456

    Google Scholar 

  203. NICE guidance for type 2 diabetes too confusing? Pharmacoecon Outcomes News 2001 Apr 14; (308)

  204. Novo Nordisk says NICE diabetes guidance causes grave concern. Marketletter 2001; 28: 27

    Google Scholar 

  205. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000 Aug; 60(2): 333–43

    Article  PubMed  CAS  Google Scholar 

  206. Matthews DR. Guidance on rosiglitazone for type 2 diabetes mellitus [letter]. Lancet 2001 Feb 10; 357: 481

    Article  PubMed  CAS  Google Scholar 

  207. Bragg T. Rosiglitazone and type 2 diabetes mellitus [letter]. Lancet 2001 May 5; 357: 1451

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Miarangi Bay, Auckland, New Zealand

    Antona J. Wagstaff & Karen L. Goa

Authors
  1. Antona J. Wagstaff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antona J. Wagstaff.

Additional information

Various sections of the manuscript reviewed by: D. Bishop-Bailey, Department of Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, London, England; J.B. Buse, Division of General Internal Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States; L.M. Chuang, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; C. Czoski-Murray, School of Health and Related Research, University of Sheffield, Sheffield, England; J. Eriksson, Diabetes and Genetic Epidemiology Unit, National Public Health Institute, Helsinki, Finland; C. Fürnsinn, Department of Internal Medicine, Division of Endocrinology and Metabolism, The General Hospital of Vienna (University), Vienna, Austria; S. Kumar, Department of Medicine, Birmingham Heartlands Hospital, Birmingham, England; A. Mooradian, Department of Internal Medicine, Division of Endocrinology, St Louis University Medical Center, School of Medicine, St Louis, Missouri, United States; S.L. Norris, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, United States; J. Petrie, University Department of Medicine, Glasgow Royal Infirmary, Glasgow, Scotland; J. Rieusset, Faculté de Médecine René Laenec, Université Claude Bernard, Lyon, France; B.H.R. Wolffenbuttel, Department of Internal Medicine, Division of Endocrinology and Metabolism, University Hospital Maastricht, Maastricht, The Netherlands.

Data Selection

Sources: Medical literature published in any language since 1980 on rosiglitazone, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: Medline search terms were ‘rosiglitazone’ or ‘BRL 49653’. EMBASE search terms were ‘rosiglitazone’ or ‘BRL 49653’. AdisBase search terms were ‘rosiglitazone’ or ‘BRL 49653’. Searches were last updated 27 June 2002.

Selection: Studies in patients with type 2 diabetes mellitus who received rosiglitazone. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Rosiglitazone, type 2 diabetes mellitus, pharmacodynamics, pharmacokinetics, therapeutic use.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagstaff, A.J., Goa, K.L. Rosiglitazone. Drugs 62, 1805–1837 (2002). https://doi.org/10.2165/00003495-200262120-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200262120-00007

Keywords

Search

Navigation